A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers
Phase
3Span
233 weeksSponsor
Jazz PharmaceuticalsIna
Recruiting
A Study of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis
Phase
3Span
228 weeksSponsor
Eli Lilly and CompanyIna, Nagano
Recruiting
1-2 of 2